Amphastar Pharmaceuticals, Inc. (AMPH)
- Previous Close
24.16 - Open
23.94 - Bid 24.18 x 100
- Ask 24.28 x 100
- Day's Range
23.93 - 24.38 - 52 Week Range
22.64 - 53.96 - Volume
342,596 - Avg. Volume
637,174 - Market Cap (intraday)
1.141B - Beta (5Y Monthly) 0.78
- PE Ratio (TTM)
8.77 - EPS (TTM)
2.76 - Earnings Date Aug 5, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
32.40
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging, as well as Albuterol Sulfate inhalation aerosol. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
www.amphastar.com2,028
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: AMPH
View MorePerformance Overview: AMPH
Trailing total returns as of 5/22/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AMPH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AMPH
View MoreValuation Measures
Market Cap
1.14B
Enterprise Value
1.55B
Trailing P/E
8.75
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.70
Price/Book (mrq)
1.52
Enterprise Value/Revenue
2.13
Enterprise Value/EBITDA
6.00
Financial Highlights
Profitability and Income Statement
Profit Margin
19.38%
Return on Assets (ttm)
7.60%
Return on Equity (ttm)
19.90%
Revenue (ttm)
730.66M
Net Income Avi to Common (ttm)
141.63M
Diluted EPS (ttm)
2.76
Balance Sheet and Cash Flow
Total Cash (mrq)
236.88M
Total Debt/Equity (mrq)
86.86%
Levered Free Cash Flow (ttm)
-3.71M